Drugs / VM110
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03286062 | Oct 2017 → Jul 2019 | malignant pancreatic neoplasm, ovarian cancer | Fox Chase Cancer Center | Terminated | No outcome recorded Stop: Enrollment |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | VM110 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03286062 ↗ |
| Modality | Diagnostic / imaging agent | “A laproscopic imaging tecgnology that uses a synthetic agent to detect ovarian and pancreatic cancers at an early stage” NCT03286062 ↗ |
| Route | Intravenous | “escalating doses of VM110 administered IV prior to laparoscopic surgery.” NCT03286062 ↗ |